$BTAX
Biostax Corp. Stock $btax

$btax Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223029368 Filed on August 18, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$233.1K	$248.9K
YoY Change	-44.61%	-14.8%
% of Gross Profit
Research & Development	$105.8K	$175.2K
YoY Change
% of Gross Profit
Depreciation & Amortization	$13.78K	$13.37K
YoY Change
% of Gross Profit
Operating Expenses	$352.3K	$437.5K
YoY Change	-16.29%	49.76%
Operating Profit	-$352.3K	-$437.5K
YoY Change	-16.29%	49.76%
Interest Expense	$36.44K	$66.76K
YoY Change	230.22%	1618.46%
% of Operating Profit
Other Income/Expense, Net	-$36.44K	-$66.76K
YoY Change	-98.24%	-103.2%
Pretax Income	-$388.8K	-$504.2K
YoY Change	-84.41%	-128.12%
Income Tax
% Of Pretax Income
Net Earnings	-$388.8K	-$504.2K
YoY Change	-84.41%	-128.12%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00	-$0.01
Diluted Earnings Per Share	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	83.62M shares	83.30M shares
Diluted Shares Outstanding	83.24M shares	83.29M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.530K	$17.43K
YoY Change	-97.63%	-93.58%
Cash & Equivalents	$4.531K	$17.43K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.531K	$17.43K
YoY Change	-97.63%	-93.58%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.500K	$5.500K
YoY Change
Total Long-Term Assets	$727.5K	$741.2K
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$4.531K	$17.43K
Total Long-Term Assets	$727.5K	$741.2K
Total Assets	$732.0K	$758.7K
YoY Change	283.35%	179.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.350M	$1.360M
YoY Change	-2.54%	-5.02%
Accrued Expenses	$136.1K	$136.1K
YoY Change	-22.72%	-55.76%
Deferred Revenue
YoY Change
Short-Term Debt	$1.984M	$1.747M
YoY Change	160.52%	-22.63%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.212M	$3.861M
YoY Change	50.79%	-43.56%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.212M	$3.861M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$4.212M	$3.861M
YoY Change	50.79%	-43.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$384.3M	-$383.9M
YoY Change	0.41%	0.97%
Common Stock	$380.8M	$380.8M
YoY Change	0.19%	1.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.480M	-$3.102M
YoY Change
Total Liabilities & Shareholders Equity	$732.0K	$758.7K
YoY Change	283.35%	179.4%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$388.8K	-$504.2K
YoY Change	-84.41%	-128.12%
Depreciation, Depletion And Amortization	$13.78K	$13.37K
YoY Change
Cash From Operating Activities	$11.06K	-$314.0K
YoY Change	-102.54%	-37.67%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-23.95K	296.5K
YoY Change	-106.84%	-12.4%
NET CHANGE
Cash From Operating Activities	11.06K	-314.0K
Cash From Investing Activities
Cash From Financing Activities	-23.95K	296.5K
Net Change In Cash	-12.89K	-17.57K
YoY Change	-85.03%	-89.37%
FREE CASH FLOW
Cash From Operating Activities	$11.06K	-$314.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001559356
CY2023Q2	IMUN	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement		usd
	IMUN	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement		usd
CY2023Q2	IMUN	Gain Loss On Assignment Of Obligations GainLossOnAssignmentOfObligations		usd
	IMUN	Gain Loss On Assignment Of Obligations GainLossOnAssignmentOfObligations		usd
CY2023Q2	IMUN	Impairment Loss On Investment In Common Stock ImpairmentLossOnInvestmentInCommonStock		usd
	IMUN	Impairment Loss On Investment In Common Stock ImpairmentLossOnInvestmentInCommonStock		usd
	IMUN	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement		usd
	IMUN	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	IMUN	Common Stock Issued For Extension Of Patent And License Agreement CommonStockIssuedForExtensionOfPatentAndLicenseAgreement		usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets		usd
	IMUN	Increase Decrease In License Fees Payable IncreaseDecreaseInLicenseFeesPayable		usd
	IMUN	Proceeds From Undocumented Investor Advances ProceedsFromUndocumentedInvestorAdvances		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodExercisePrice
	IMUN	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAveragePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	IMUN	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodExercisePrice
	IMUN	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAveragePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-54933
	dei	Entity Registrant Name EntityRegistrantName	IMMUNE THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-3226705
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2431 Aloma Ave.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 124
	dei	Entity Address City Or Town EntityAddressCityOrTown	Winter Park
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32792
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	613-8802
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83620764	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17426	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150491	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	17426	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	150491	usd
CY2023Q2	IMUN	Patents And Licenses PatentsAndLicenses	735746	usd
CY2022Q4	IMUN	Patents And Licenses PatentsAndLicenses	762500	usd
CY2023Q2	us-gaap	Deposits Assets DepositsAssets	5500	usd
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	50728	usd
CY2023Q2	us-gaap	Assets Assets	758672	usd
CY2022Q4	us-gaap	Assets Assets	963719	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1359562	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1300366	usd
CY2023Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	336002	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	336002	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	1111478	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	696478	usd
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	104063	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	64455	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	136057	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	136057	usd
CY2023Q2	IMUN	License Fees Payable Current LicenseFeesPayableCurrent	178793	usd
CY2022Q4	IMUN	License Fees Payable Current LicenseFeesPayableCurrent	549079	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3861022	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3477173	usd
CY2023Q2	us-gaap	Liabilities Liabilities	3861022	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3477173	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83598763	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83598763	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83045857	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83045857	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	8360	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8305	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	380767830	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	380436432	usd
CY2023Q2	IMUN	Stock Issuances Due StockIssuancesDue	10303	usd
CY2022Q4	IMUN	Stock Issuances Due StockIssuancesDue	10303	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-383888844	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-382968494	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3102351	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	758672	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	963719	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	248886	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	292117	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	456403	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	473733	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	175209	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	356132	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13377	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	26754	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	437472	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	292117	usd
	us-gaap	Operating Expenses OperatingExpenses	839289	usd
	us-gaap	Operating Expenses OperatingExpenses	473733	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-437472	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-292117	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-839289	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-473733	usd
CY2022Q2	IMUN	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement	3165151	usd
	IMUN	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement	3165151	usd
CY2022Q2	IMUN	Gain Loss On Assignment Of Obligations GainLossOnAssignmentOfObligations	297579	usd
	IMUN	Gain Loss On Assignment Of Obligations GainLossOnAssignmentOfObligations	297579	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1011625	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1011625	usd
CY2022Q2	IMUN	Impairment Loss On Investment In Common Stock ImpairmentLossOnInvestmentInCommonStock	362250	usd
	IMUN	Impairment Loss On Investment In Common Stock ImpairmentLossOnInvestmentInCommonStock	2645000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	66762	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	3885	usd
	us-gaap	Interest Expense InterestExpense	81061	usd
	us-gaap	Interest Expense InterestExpense	96069	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-66762	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2084970	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-81061	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-289964	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-504234	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	1792853	usd
	us-gaap	Net Income Loss NetIncomeLoss	-920350	usd
	us-gaap	Net Income Loss NetIncomeLoss	-763697	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-504234	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1792853	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-920350	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-763697	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.29
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.29
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83285054	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	696752	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83381739	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	590822	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83285054	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7804548	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83381739	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	590822	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7948256	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	479000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2474	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	648324	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1011625	usd
	us-gaap	Net Income Loss NetIncomeLoss	-763697	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6569630	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
	IMUN	Stock Issued During Period Value Issued For Extension Of Patent And License Agreement StockIssuedDuringPeriodValueIssuedForExtensionOfPatentAndLicenseAgreement	300000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	31453	usd
	us-gaap	Net Income Loss NetIncomeLoss	-920350	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3102351	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3102351	usd
	us-gaap	Net Income Loss NetIncomeLoss	-920350	usd
	us-gaap	Net Income Loss NetIncomeLoss	-763697	usd
	IMUN	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement	3165151	usd
	IMUN	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations	297579	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2645000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1011625	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26754	usd
	IMUN	Common Stock Issued For Extension Of Patent And License Agreement CommonStockIssuedForExtensionOfPatentAndLicenseAgreement	300000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-45228	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-340804	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-146811	usd
	IMUN	Increase Decrease In License Fees Payable IncreaseDecreaseInLicenseFeesPayable	29714	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4620	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	39608	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	83265	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	67960	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	240331	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-579519	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-560768	usd
	IMUN	Proceeds From Undocumented Investor Advances ProceedsFromUndocumentedInvestorAdvances	6369	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	100000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	322047	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	346453	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	446453	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	338416	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-133066	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-222352	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	150491	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	493885	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17426	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	271533	usd
	IMUN	Conversion Of Notes And Accrued Interest To Common Stock ConversionOfNotesAndAccruedInterestToCommonStock	31453	usd
	IMUN	Conversion Of Notes And Accrued Interest To Common Stock ConversionOfNotesAndAccruedInterestToCommonStock	1128224	usd
CY2023Q2	us-gaap	Cash Cash	17426	usd
CY2023Q2	IMUN	Working Capital WorkingCapital	3843596	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-383888844	usd
	us-gaap	Net Income Loss NetIncomeLoss	-920350	usd
	us-gaap	Net Income Loss NetIncomeLoss	-763697	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zxjP22I1Jzyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zjsVnoAsl59g">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-920350	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-763697	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83381739	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	590822	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.29
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17426	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150491	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zPotywQprs58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zDBsen4sOaoe">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20230630_zK0g9xlHl4p" title="Cash at federal deposit">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-920350	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-763697	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83381739	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	590822	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.29
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	356132	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-504234	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1792853	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83285054	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	696752	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.57
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-504234	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1792853	usd
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83285054	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7804548	shares
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	1111478	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	696478	usd
CY2023Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	104062	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	64455	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1011625	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1011625	usd
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y7M17D
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	33495	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	38495	shares
CY2022Q4	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice	59.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	5000	shares
	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAveragePrice	66.00
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	33495	shares
CY2023Q2	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice	58.44
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure

Files In Submission

Name	View Source	Status
0001493152-23-029368-index-headers.html	Edgar Link	pending
0001493152-23-029368-index.html	Edgar Link	pending
0001493152-23-029368.txt	Edgar Link	pending
0001493152-23-029368-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
imun-20230630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
imun-20230630_def.xml	Edgar Link	unprocessable
imun-20230630_lab.xml	Edgar Link	unprocessable
imun-20230630_cal.xml	Edgar Link	unprocessable
imun-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BTAX
Biostax Corp. Stock $btax

2023 Q3 Form 10-Q Financial Statement

#000149315223029368 Filed on August 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTAX Biostax Corp. Stock $btax

2023 Q3 Form 10-Q Financial Statement

#000149315223029368 Filed on August 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTAX
Biostax Corp. Stock $btax